Home

Welcome to ECTRIMS

The European Committee for Treatment and Research in Multiple Sclerosis is a non-profit, independent, representative European-wide organisation that serves as Europe’s and the world’s largest professional organisation dedicated to the understanding and treatment of multiple sclerosis.

ECTRIMS Bulletin: August

New research highlights how COVID-19 has changed physical therapy for MS patients; bolstering the blood-CNS barrier could lead to new MS treatments, & a new study provides insight on disease reactivation

> Read more

Exploring MS & Quality of Life

What key factors impact quality of life in people with multiple sclerosis? Our latest ECTRIMS Insight explores the importance of QoL for MS patients, a key topic featured being featured at ECTRIMS 2022.

> Read more

Celebrating ECTRIMS Fellowships

Watch MS nurse Francesco Pastore, a 2018 Nurse and AHP Fellowship recipient speak about the key takeaways of his fellowship experience, in celebrations marking the 15th year of the ECTRIMS fellowship programme.

> Watch the Collection

Celebrating 15 Years of ECTRIMS Fellowships

ECTRIMS 2022: Experience the Evolution

Apply for a 2023 ECTRIMS Fellowship

Experience the Evolution: Register for ECTRIMS 2022

Digitally United - Wrapping up ECTRIMS 2021

EAN/ECTRIMS Vaccination Standards for MS patients

ECTRIMS 2021:
Be part of an outstanding digital experience 13-15 October 2021

ECTRIMS Focused Workshop 2021 - Highlights

Stay connected

Find below our Twitter-Feed to get the hottest news.

ECTRIMS @ECTRIMS·

25 Sep

Share insights on #MSresearch & meet peers from around the world at #ECTRIMS2022 on ... 26–28 Oct. From hot topics to meet the expert sessions, the congress provides an invaluable platform for learning & engagement in #MS research, treatment and care.

➡️ https://bit.ly/3uw29rG

ECTRIMS @ECTRIMS·

23 Sep

#MSJournal: Research from @MayoClinic shows: CMJ “critical” lesions can correlate ... with progressive motor impairment even with few or no additional MRI lesions. Lesion location is a determinant of progressive motor impairment in demyelinating disease.

https://bit.ly/3SbBTNo

ECTRIMS @ECTRIMS·

22 Sep

Attendees can explore the latest research on vaccinations and #MS across 42 different ... vaccination-related topics at #ECTRIMS2022. To find out more, see our searchable programme ➡️ https://bit.ly/3DcIy5z

ECTRIMS @ECTRIMS·

21 Sep

⏰ The countdown has begun! Don’t miss your opportunity to be part of #ECTRIMS2022 ... evolution in Amsterdam in just six weeks’ time. Register now to share insights and strengthen networks within your MS research community ➡️ https://bit.ly/3uw29rG

ECTRIMS @ECTRIMS·

21 Sep

#MSJournal: @AmjadAltokhais, @HibbertAimee et al. from @UniofNottingham conclude in ... their research that the presence and number of perilesional IR on MRI hold prognostic value for long-term clinical disability in #MS.

https://bit.ly/3S2jtis

ECTRIMS @ECTRIMS·

21 Sep

⏰ Only six weeks remain until #ECTRIMS2022 in Amsterdam on 26–28 Oct. This year's ... congress will be a particularly special one. Register now to experience the ECTRIMS evolution with leading #MS researchers and practitioners ➡️ https://bit.ly/3uw29rG

Click here to > Load More

ECTRIMS Bulletin: August

Exploring MS & Quality of Life

Celebrating ECTRIMS Fellowships

Celebrating 15 Years of ECTRIMS Fellowships

ECTRIMS 2022: Experience the Evolution

Apply for a 2023 ECTRIMS Fellowship

Experience the Evolution: Register for ECTRIMS 2022

Digitally United - Wrapping up ECTRIMS 2021

EAN/ECTRIMS Vaccination Standards for MS patients

ECTRIMS 2021:Be part of an outstanding digital experience 13-15 October 2021

ECTRIMS Focused Workshop 2021 - Highlights

Stay connected

ECTRIMS 2021:
Be part of an outstanding digital experience 13-15 October 2021